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Summary
Background WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of 
communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines 
is very low, but now aim to assess how such low use relates to their lack of availability or poor aﬀ ordability.
Methods We analysed information about availability and costs of cardiovascular disease medicines (aspirin, β blockers, 
angiotensin-converting enzyme inhibitors, and statins) in pharmacies gathered from 596 communities in 18 countries 
participating in the Prospective Urban Rural Epidemiology (PURE) study. Medicines were considered available if 
present at the pharmacy when surveyed, and aﬀ ordable if their combined cost was less than 20% of household 
capacity-to-pay. We compared results from high-income, upper middle-income, lower middle-income, and low-income 
countries. Data from India were presented separately given its large, generic pharmaceutical industry.
Findings Communities were recruited between Jan 1, 2003, and Dec 31, 2013. All four cardiovascular disease medicines 
were available in 61 (95%) of 64 urban and 27 (90%) of 30 rural communities in high-income countries, 53 (80%) of 
66 urban and 43 (73%) of 59 rural communities in upper middle-income countries, 69 (62%) of 111 urban and 
42 (37%) of 114 rural communities in lower middle-income countries, eight (25%) of 32 urban and one (3%) of 
30 rural communities in low-income countries (excluding India), and 34 (89%) of 38 urban and 42 (81%) of 52 rural 
communities in India. The four cardiovascular disease medicines were potentially unaﬀ ordable for 0·14% of 
households in high-income countries (14 of 9934 households), 25% of upper middle-income countries (6299 of 
24 776), 33% of lower middle-income countries (13 253 of 40 023), 60% of low-income countries (excluding India; 
1976 of 3312), and 59% households in India (9939 of 16 874). In low-income and middle-income countries, patients 
with previous cardiovascular disease were less likely to use all four medicines if fewer than four were available 
(odds ratio [OR] 0·16, 95% CI 0·04–0·57). In communities in which all four medicines were available, patients were 
less likely to use medicines if the household potentially could not aﬀ ord them (0·16, 0·04–0·55).
Interpretation Secondary prevention medicines are unavailable and unaﬀ ordable for a large proportion of communities 
and households in upper middle-income, lower middle-income, and low-income countries, which have very low use 
of these medicines. Improvements to the availability and aﬀ ordability of key medicines is likely to enhance their use 
and help towards achieving WHO’s targets of 50% use of key medicines by 2025.
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Introduction
17 million people are estimated to die of cardiovascular 
diseases worldwide every year.1 About 20% occur in 
those with known vascular disease.2 Many of these 
deaths could be avoided if the use3 of proven medicines 
among patients with vascular disease (secondary 
prevention) were increased. Clinical guidelines recom-
mend the use of four medicines for the secondary 
prevention of cardiovascular disease: aspirin, β blockers, 
angiotensin-converting enzyme (ACE) inhibitors or 
angiotensin-II receptor blockers (ARBs), and statins.4 
However, in a previous report from the Prospective 
Urban Rural Epidemiology (PURE) study, only 25% of 
patients with established cardiovascular disease were 
taking aspirin, 17% β blockers, 20% ACE inhibitors or 
ARBs, and 15% statins. In high-income countries, 11% of 
eligible patients were not taking any of these medicines, 
compared with 80% in low-income countries.3
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WHO’s Global Action Plan has set a goal to achieve 
50% use of medicines recommended for the prevention 
of cardiovascular disease worldwide by 2025.5 To reach 
this goal, these medicines need to be made widely 
available and aﬀ ordable.
In this Article, we aim to document the availability of 
aspirin, β blockers, ACE inhibitors, and statins in 
community pharmacies and assess their aﬀ ordability at 
diﬀ erent country incomes. We then relate availability and 
aﬀ ordability of medicines to their use in patients with 
cardiovascular disease from 18 countries.
Methods
Study design and participants
We did a post-hoc analysis of the PURE study, using data 
from 94 919 households with reported household incomes 
from 596 communities in 18 countries and 7013 people 
with cardiovascular disease. Individuals in households 
that reported or did not report income were generally 
similar (appendix).
Countries were selected to ensure a range of economic 
development, and the feasibility to collect high-quality 
data and complete long-term follow-up.6 In every country 
chosen, communities were selected from urban and 
rural locations. In the PURE study, communities were 
deﬁ ned as a group of people who have common 
characteristics and reside in a deﬁ ned geographical area.3 
In each community, we sought to have a representative 
sample of adults aged 35–70 years. The characteristics 
and death rates of the study population were similar to 
their national populations.7
Additional details on methods, sampling and selection 
of countries, communities, and individuals have been 
published previously.6,8,9 Ethics committees at each 
centre approved the protocol, which has been published 
elsewhere;6,8,9 all participants provided written informed 
consent.6
Data collection and deﬁ nitions
Data for availability and costs of medicines were 
collected from one community pharmacy in each 
community with the Environmental Proﬁ le of a 
Community’s Health (EPOCH) instrument, which 
recorded information about environmental and societal 
factors that can aﬀ ect cardiovascular disease.10 Only 
communities with at least 30 PURE participants were 
Research in context
Evidence before this study
We searched the PubMed database for articles about the 
availability and aﬀ ordability of medicines for the secondary 
prevention of cardiovascular disease in countries at various 
stages of economic development published before May 1, 2014, 
without language restrictions. Our search terms included 
“availability”, “aﬀ ordability”, “secondary prevention”, “CVD 
medicines or drugs”, “low-income countries”, and 
“middle-income countries”. We excluded studies that did not 
provide data for at least one of the four medicines 
recommended for the secondary prevention of cardiovascular 
disease (aspirin, β blockers, angiotensin-converting enzyme 
inhibitors or angiotensin-II receptor blockers, or statins), or a 
measure of aﬀ ordability for the medicines.
We identiﬁ ed ﬁ ve reports that used diﬀ erent methods to 
measure the availability and aﬀ ordability of diﬀ erent medicines 
for cardiovascular disease. Only one report considered the 
availability and aﬀ ordability of the four medicines recommended 
by clinical guidelines. That report included data from 
ﬁ ve low-income and middle-income countries, and as a measure 
for aﬀ ordability used the number of days wages it would cost the 
lowest paid government worker to purchase 1 month of 
treatment. Aﬀ ordability varied by country; however, in view of 
the method used, the number of days wages that made 
treatment unaﬀ ordable (ie, a cutoﬀ  point to determine 
aﬀ ordability) could not be determined. Additionally, information 
about the use of these medicines in the communities described 
was not collected and therefore the eﬀ ects of little availability 
and aﬀ ordability on use could not be deduced.
Added value of this study
To our knowledge, our study is the ﬁ rst to describe the availability 
and aﬀ ordability of the four medicines recommended for the 
secondary prevention of cardiovascular disease in high-income, 
upper middle-income, lower middle-income, and low-income 
countries. It is also the ﬁ rst to relate these factors to medicine use. 
Our results suggest that the availability and aﬀ ordability of these 
medicines is low in low-income and middle-income countries, 
which correlates with low rates of use. In India, these medicines 
are available in most communities given the large production of 
generic-brand medicines in the country. However, they remain 
unaﬀ ordable for large proportions of the community.
Implications of all the available evidence
Clinical guidelines recommend the use of four medicines for the 
secondary prevention of cardiovascular disease. However, the 
medicines remain unavailable and unaﬀ ordable for large 
proportions of communities in low-income and middle-income 
countries. Although our results show substantially lower use of 
key medicines when they are not available or unaﬀ ordable, it 
does not automatically mean that improving availability or 
aﬀ ordability by themselves will increase their use. Additional 
research on how additional factors might further aﬀ ect use of 
these medicines is needed (eg, access to health-care providers 
and attitudes to prevention on the part of both physicians and 
patients). Research on this topic is especially scarce in 
low-income and middle-income countries. Strategies to make 
proven medicines more available and aﬀ ordable are crucially 
needed to increase their use in low-income and middle-income 
countries where the burden of cardiovascular disease is growing.
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included in EPOCH (90% of PURE communities). This 
instrument has been shown to be a reliable and feasible 
indicator of measures of the health environment in 
diverse settings.10
Data collection methods included an observation walk, 
whereby trained ﬁ eld researchers walked according to 
a planned route covering 1 km, beginning from a 
prespeciﬁ ed central location designated as the starting 
point (a central area that people frequently visit, eg, busy 
intersections or a train station).10 A pharmacy closest to 
the starting point was visited to collect information 
about availability and costs of medicines. If a pharmacy 
was not located within the 1 km observation walk, 
researchers were instructed to search for a pharmacy 
located up to 20 km from the starting point from which 
to gather data.
Information about the availability and cost of 
three ACE inhibitors (captopril, enalapril, and ramipril), 
two β blockers (atenolol and metoprolol), two statins 
(simvastatin and atorvastatin), and aspirin were 
gathered. Field researchers were instructed to gather 
information about the most common trade name for 
each of these medicine types as identiﬁ ed by the 
pharmacist. Although clinical guidelines recommend 
the use of either ACE inhibitors or ARBs, ARBs seem 
to be rarely used in low-income and middle-income 
countries.
Trained interviewers collected data at the household 
and individual levels with standardised questionnaires. 
Household income per month and expenditures on 
food were recorded from a knowledgeable member in 
each participating household. Information about 
previous cardiovascular disease and medicine use were 
obtained from consenting household members aged 
35–70 years.6 Cardiovascular disease was deﬁ ned as an 
individual with previous stroke or coronary heart 
disease (eg, myocardial infarction, coronary artery 
bypass graft surgery, percutaneous coronary angioplasty, 
or angina). Self-reported events from PURE have been 
previously validated against medical records, with a 
conﬁ rmation rate of 89%.3
The use of any medicine was deﬁ ned as taking it at 
least once per week in the past month. Names of all 
medicines taken were recorded by direct inspection 
of medicines or prescriptions at face-to-face assessments.3 
Medicines were centrally coded into medicine classes by 
trained staﬀ  (eg, aten and betacard were coded as atenolol 
and lipitor as atorvastatin). Availability was deﬁ ned as the 
presence of all four medicines (aspirin, β blockers, ACE 
inhibitors, and statins) at any dose in the pharmacy on 
the day of the survey. Costs are presented for a month’s 
supply of all four medicines at standard doses and 
recommended frequencies (appendix). Aﬀ ordability was 
expressed as the total monthly cost of the four medicines 
as a proportion of monthly household capacity-to-pay—
the household income remaining after basic subsistence 
needs have been met. We deﬁ ned subsistence needs as 
the household monthly income spent on food, which is 
consistent with scientiﬁ c literature of catastrophic health 
expenditures.11,12
Combined costs of the four medicines were deemed 
aﬀ ordable if they comprised less than an arbitrary 
threshold of 20% of a household’s capacity-to-pay.12 
Sensitivity analyses for thresholds ranging from 10% to 
50% of household capacity-to-pay are also presented. 
This approach of presenting aﬀ ordability of medicines 
was developed by Niens and colleagues12,13 as an 
extension of methods used to assess catastrophic health 
expenditure. Details on how aﬀ ordability was calculated 
and validation of capacity-to-pay values are listed in 
the appendix.
The appendix shows that household capacity-to-pay 
values were correlated with household wealth index 
scores (r=0·71, p<0·0001). Median country household 
capacity-to-pay calculated from the PURE study also 
correlated well with capacity-to-pay values from the 
WHO World Health Survey14 (r=0·85, p=0·0035), and per 
capita country income from the World Bank15 (r=0·88, 
p<0·0001). Thus, capacity-to-pay values collected by the 
PURE study have reasonable external validity.
In any multinational study, variations in health systems 
within and across countries aﬀ ect the standardised 
assessment of the availability and aﬀ ordability of medicines. 
For example, the PURE study collected information on the 
availability of medicines in the pharmacy only; therefore, 
their availability in non-pharmacy sources is not known. 
Thus, our analyses reﬂ ect potential availability (ie, based on 
the assumption that patients buy their medicines from a 
nearby pharmacy).
Payment methods for medicines also vary by country, 
within regions in a country, and by individuals within 
each country. For example, public pharmacies might 
oﬀ er speciﬁ c medicines free of charge to speciﬁ c 
population groups (eg, people with low income). 
However, previously reported data for the availability 
of medicines in upper middle-income and lower 
middle-income countries suggest that availability is 
lower in the public system than the private system,16 
forcing patients to purchase medicines at full costs from 
non-governmental sources. Additionally, worldwide, 
patients who have some form of insurance pay a fraction 
or none of these costs; however, assessments indicate 
that in lower-income countries, insurance does not cover 
medicine costs and many patients purchase these 
through out-of-pocket payments.17 The PURE study did 
not collect information about actual costs that participants 
paid for each medicine. Therefore, our analyses represent 
potential aﬀ ordability for households (ie, based on the 
assumption that each household paid full cost).
Statistical analysis
We describe the potential availability of aspirin, β blockers, 
ACE inhibitors, and statins in 596 communities included 
in PURE and the potential aﬀ ordability of these for 
See Online for appendix
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1 month’s supply to 94 919 households. Associations 
between availability and aﬀ ordability and use of medicines 
were analysed in 7013 patients with known cardiovascular 
disease. Few patients were using all four medicines so we 
present additional post-hoc analyses for the associations 
between the availability and aﬀ ordability of at least 
three of the medicines and the use of at least three.
Data were analysed using multilevel, mixed-eﬀ ects 
logistic regression models, accounting for clustering at 
the community and household levels. Statistical models 
were adjusted for possible confounders: age, sex, 
education level, urban and rural setting, years since 
cardiovascular disease diagnosis, use of other medicines 
(eg, for diabetes or pain relief), cancer diagnosis, smoking 
status, and number of household members (either fewer 
than ﬁ ve or ﬁ ve or more).18 Adjusted and unadjusted 
associations between availability and aﬀ ordability and 
medicine use were reported as odds ratios (OR) and 
95% conﬁ dence intervals. We used Stata (version 13.0) for 
all statistical analyses.
Household incomes and medicine costs were 
standardised to 2010 prices by inﬂ ation rates from the 
World Bank.15 As secondary analyses, income and cost 
data were converted from local currency to US$ adjusted 
for purchasing power parity in 2010, as reported by the 
World Bank.19 Results were presented as the median 
(IQR) of all participants in high-income, upper 
middle-income, lower middle-income, and low-income 
country groups. Data from India were presented 
separately from other low-income countries because of 
its large generic pharmaceutical industry.20 In the 
appendix are the results at the country level in order 
from highest to lowest per capita gross national income.
Role of funding source
The funders of the study had no role in its design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding and lead (SY and RKh) 
authors had full access to all the data in the study and all 
authors had ﬁ nal responsibility for the decision to submit 
for publication. 
Results
Recruitment of participants began in January, 2003, 
with most recruitment completed between 2005 and 
2009.9 Data for 94 919 eligible households’ incomes were 
collected between Jan 1, 2003, and Dec 31, 2013, and for 
medicine costs were collected between Jan 1, 2009, and 
Dec 31, 2013. The analyses include three high-income 
countries (Sweden, United Arab Emirates, and Canada; 
94 communities, 9934 households), seven upper 
middle-income countries (Poland, Turkey, Chile, 
Malaysia, South Africa, Argentina, and Brazil; 
125 communities, 24 776 households), four lower 
middle-income countries (Colombia, Iran, China, and 
the occupied Palestinian territory; 225 communities, 
Number of 
communities
Number of 
households
Number of 
participants with 
cardiovascular 
disease
Total 596 94 919 7013
High-income countries 94 9934 691
Sweden 23 2427 121
United Arab Emirates 3 953 64
Canada 68 6554 506
Upper middle-income countries 125 24 776 1499
Poland 4 1499 140
Turkey 38 2553 293
Chile 5 2222 109
Malaysia 35 10 471 420
South Africa 9 2168 104
Argentina 20 2158 100
Brazil 14 3705 333
Lower middle-income countries 225 40 023 3918
Colombia 58 5069 251
Iran 20 2992 229
China 108 30 409 3336
Occupied Palestinian territory 39 1553 102
Low-income countries (excluding India) 62 3312 219
Pakistan 4 1043 117
Bangladesh 55 2001 80
Zimbabwe 3 268 22
India 90 16 874 686
Classiﬁ cation of countries by income groups refer to World Bank classiﬁ cations at the time of data collection (2006).
Table 1: Countries included i n analyses with number of communities, households, and patients with 
cardiovascular disease
Figure 1: Percentage availability of the four cardiovascular disease medicines 
in the 596 PURE communities surveyed
n=total number of communities in each location of each country income group. 
Cardiovascular medicines included aspi rin, β blockers, angiotensin-converting 
enzyme inhibitors, and statins. The value for the ptrend comparing high-income 
countries (HIC), upper middle-income countries (UMIC), lower middle-income 
countries (LMIC), and low-income countries (LIC; excluding India) was calculated 
using the trend test across a two by k table. ptrend<0·0001 both in total and 
separately for urban and rural communities for all the diﬀ erent country income 
groups. *Excluding India.
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40 023 households), and three low-income countries 
excluding India (Pakistan, Bangladesh, and Zimbabwe; 
62 communities, 3312 house holds), in addition to India 
(90 communities, 16 874 households; table 1).
The availability of all four medicines was highest in 
high-income countries (95% [n=61] urban and 90% [n=27] 
rural communities) and in India (89% [n=34] urban and 
81% [n=42] rural) and lowest in low-income countries 
excluding India (25% [n=8] urban and 3% [n=1] rural). 
Availability was intermediate in upper middle-income 
countries (80% [n=53] urban and 73% [n=43] rural) and 
lower middle-income countries (62% [n=69] urban and 
37% [n=42] rural; ﬁ gure 1). The appendix presents the 
availability of each of these four medicines by country’s 
income group.
A patient with cardiovascular disease in urban and 
rural high-income countries would potentially need to 
spend a median of 1% (IQR 0·5–3 for urban and 
0·5–2 for rural) of their household capacity-to-pay to 
buy all four cardiovascular disease medicines (ﬁ gure 2). 
The median spend for all four medicines would be 5% 
(IQR 2–13) in urban and 11% (5–34) in rural upper 
middle-income countries, 6% (1–23) in urban and 11% 
(4–97) in rural lower middle-income countries, 17% 
(10–37) in urban and 49% (20–100) in rural low-income 
countries (excluding India), and 13% (5–43) in urban 
and 68% (23–100) in rural India. Furthermore, the costs 
of aspirin and β blockers were lower than the costs of 
ACE inhibitors and statins across the diﬀ erent countries’ 
income groups (ﬁ gure 2). Median cost of each medicine 
as a proportion of household capacity-to-pay is presented 
in the appendix.
Median monthly household capacity-to-pay and the 
median monthly cost of the four medicines (in US$ 
adjusted for purchasing power parity) are listed 
in table 2. The capacity-to-pay is highest among 
high-income country households and lowest in Indian 
and other low-income country households. Cost of 
medicines shows a similar trend across the diﬀ erent 
country income groups. However, the variability in the 
cost of the four medicines is less striking than variability 
in capacity-to-pay values: the median monthly 
capacity-to-pay is $4238 among high-income country 
households, and $89 among low-income country 
households excluding India (48 times higher in 
high-income countries than in low-income countries 
[excluding India]). By contrast, the median monthly 
cost of the four medicines is $61 in high-income 
countries compared with $17 in low-income countries, 
excluding India (only four times higher in high-income 
countries than in low-income countries excluding 
India). The median cost of each medicine was low in 
Iran and the occupied Palestinian territory compared 
with other countries in the same income group, which 
tended to decrease the overall cost in lower 
middle-income countries. These essential medicines 
are subsidised by the governments in Iran and the 
occupied Palestinian territory.
Using a threshold of 20% for household capacity-to-
pay to deﬁ ne what is potentially unaﬀ ordable, our 
results show that 6299 (25%) and 13 253 (33%) 
households in upper middle-income countries and 
lower middle-income countries, respectively, would ﬁ nd 
Figure 2: Median monthly cost of each of the four cardiovascular medicines 
as a percentage of a household’s capacity-to-pay
Data are median (%) of 94 919 households. ACE=angiotensin-converting enzyme. 
HIC=high-income countries. UMIC=upper middle-income countries. LMIC=lower 
middle-income countries. LIC=low income-countries. *Excluding India.
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Country income level
UMIC LMIC LIC* India
Statins
ACE inhibitors
β blockers
Aspirin
Capacity-to-pay 
(US$)
Total cost of all 
four medicines* (US$)
Cost of aspirin 
(US$)
Cost of β blockers 
(US$)
Cost of ACE 
inhibitors (US$)
Cost of statins 
(US$)
High-income countries 4238 (2280–6180) 61 (18–91) 3 (2–7) 10 (3–16) 15 (5–23) 34 (8–46)
Upper middle-income countries 436 (176–989) 35 (18–44) 4 (2–6) 6 (2–7) 10 (7–15) 5 (5–16)
Lower middle-income countries 243 (108–463) 16 (7–50) 0·2 (0·1–3) 0·6 (0·1–13) 0·6 (0·3–2) 6 (2–17)
Low-income countries 
(excluding India)†
89 (34–173) 17 (17–42) 0·5 (0·5–0·7) 0·7 (0·7–4) 2 (2–9) 14 (14–21)
India 84 (27–317) 30 (26–35) 0·4 (0·3–0·6) 4 (3–4) 8 (8–9) 16 (13–21)
Costs are median (IQR) of 94 919 households, adjusted for purchasing power parity. ACE=angiotensin-converting enzyme. *The sum of the medians for each medicine 
(aspirin, β blockers, ACE inhibitors, and statins) is not necessarily the same as the median of the total cost for the four medicines. †Zimbabwe was not included in this analysis 
because purchasing power parity values were not available. 
Table 2: Monthly household capacity-to-pay, and costs of each of the four cardiovascular disease medicines in diﬀ erent countries
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medicines unaﬀ ordable. 1976 (60%) households in 
low-income countries (excluding India) and 9939 (59%) 
households in India would ﬁ nd medicines unaﬀ ordable. 
In high-income countries, only 14 (0·14%) households 
would be unable to aﬀ ord medicines—should they have 
to pay full costs. A sensitivity analysis, using thresholds 
that ranged from 10% to 50% of household capacity-to-
pay, shows a similar pattern (appendix).
Among patients in the highest wealth groups, 433 (5%) 
patients in upper middle-income, 2776 (21%) in lower 
middle-income, 482 (45%) in low-income countries 
(excluding India), and 1476 (26%) patients in India could 
not aﬀ ord the four medicines recommended for the 
secondary prevention of cardiovascular disease (ﬁ gure 3). 
These analyses show that even medicines regarded as 
being low cost are potentially unaﬀ ordable by a large 
proportion of even the richer segments of low-income 
and middle-income countries.
Further analyses were restricted to the 7013 participants 
who reported a history of cardiovascular disease. Of 
patients with cardiovascular disease, use of each 
medicine was lower in low-income countries including 
India than in high-income countries. Overall, 205 (3%)
patients reported using all four medicines, 686 (10%) 
reported using at least three, 1448 (21%) reported using at 
least two, and 2589 (37%) reported using at least 
one medicine; 2085 (30%) patients did not take any 
medicines. Medicine use varied substantially by wealth 
in upper middle-income countries, lower middle-income 
countries, India, and other low-income countries 
(table 3). However, across wealth tertiles use was similar 
in high-income countries (table 3).
In high-income countries medicines were available and 
aﬀ ordable for most patients and estimates of associations 
with use could not be calculated. The number of patients 
who reported using all four medicines was small within the 
remaining country income groups. So our main analyses 
present estimates for upper middle-income countries, 
lower middle-income countries, low-income countries 
(excluding India), and India under one wealth category: 
low-income and middle-income countries. Results for each 
country income group are presented in the appendix.
Table 4 presents the adjusted and unadjusted 
relationships between lack of availability and aﬀ ordability 
and use in low-income and middle-income countries. 
Patients living in communities with low availability of all 
four medicines were less likely to use them (OR 0·16, 
95% CI 0·04–0·57) than communities that had all 
four medicines available. Patients living in communities 
where the medicines were available but who were unable 
to aﬀ ord the medicines (using a threshold of 20%) were 
also less likely to use them (0·16, 0·04–0·55). The number 
of patients using the four medicines was small (n=205), so 
we also present the eﬀ ects of availability and aﬀ ordability 
of at least three medicines on use of at least three medicines 
(n=686). The results are similar but are statistically more 
robust compared with use of all four medicines.
Figure 3: Proportion of households that might not be able to aﬀ ord all four cardiovascular disease medicines 
(using a 20% threshold) by tertiles of wealth index
Data are of 94 919 households. HIC=high-income countries. UMIC=upper middle-income countries. LMIC=lower 
middle-income countries. LIC=low-income countries. *Excluding India.
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Country income level
UMIC LMIC LIC* India
Lowest wealth Middle wealth Highest wealth
At least 
one medicine
At least 
two medicines
At least 
three medicines
All 
four medicines
Total 2589/7013 (37%) 1448/7013 (21%) 686/7013 (10%) 205/7013 (3%)
High-income countries
Lowest wealth 251/281 (89%) 203/281 (72%) 131/281 (47%) 43/281 (15%)
Middle wealth 164/180 (91%) 143/180 (79%) 88/180 (49%) 35/180 (19%)
Highest wealth 204/230 (89%) 167/230 (73%) 108/230 (47%) 44/230 (19%)
All high-income countries 619/691 (90%) 513/691 (74%) 327/691 (47%) 122/691 (18%)
Upper middle-income countries
Lowest wealth 213/502 (42%) 111/502 (22%) 44/502 (9%) 7/502 (1%)
Middle wealth 272/501 (54%) 163/501 (33%) 68/501 (14%) 29/501 (6%)
Highest wealth 310/496 (63%) 203/496 (41%) 110/496 (22%) 27/496 (5%)
All upper middle-income 
countries
795/1499 (53%) 477/1499 (32%) 222/1499 (15%) 63/1499 (4%)
Lower middle-income countries
Lowest wealth 220/1325 (17%) 61/1325 (5%) 11/1325 (1%) 1/1325 (0·1%)
Middle wealth 343/1290 (27%) 120/1290 (9%) 31/1290 (3%) 6/1290 (0·5%)
Highest wealth 446/1303 (34%) 212/1303 (16%) 73/1303 (6%) 10/1303 (1%)
All lower middle-income 
countries
1009/3918 (26%) 393/3918 (10%) 115/3918 (3%) 17/3918 (0·4%)
Low-income countries*
Lowest wealth 3/79 (4%) 1/79 (1%) 1/79 (1%) 0/79 (0%)
Middle wealth 9/71 (13%) 1/71 (2%) 0/71 (0%) 0/71 (0%)
Highest wealth 26/69 (38%) 10/69 (14%) 1/69 (2%) 0/69 (0%)
All low-income countries 38/219 (17%) 12/219 (5%) 2/219 (1%) 0/219 (0%)
India
Lowest wealth 13/228 (6%) 3/228 (1%) 0/228 (0%) 0/228 (0%)
Middle wealth 29/236 (12%) 18/236 (8%) 10/236 (4%) 1/236 (0·4%)
Highest wealth 86/220 (39%) 32/220 (15%) 10/220 (5%) 2/220 (1%)
All India 128/686 (19%) 53/686 (8%) 20/686 (3%) 3/686 (0·4%)
Data are n/N (%) from 7013 patients. Cardiovascular disease medicines included aspirin, β blockers, 
angiotensin-converting enzyme inhibitors, and statins. *Excluding India.
Table 3: Participants with a history of cardiovascular disease who reported medicine use across tertiles of 
income in a range of country incomes
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Comparisons of use of individual medicines in India 
(where availability is high, but aﬀ ordability is low) and 
other low-income countries (where both availability and 
aﬀ ordability are low) show little diﬀ erence in the use of 
aspirin, but relatively higher rates of use of β blockers, 
ACE inhibitors, and statins in India (appendix). 
However, in both groups of countries the use of these 
medicines were low, suggesting that improvements in 
availability without improvements in aﬀ ordability are 
unlikely to result in a major increase in the prevalence 
of these medicines being used. Our results also suggest 
that when the four medicines are both available 
and aﬀ ordable, only 122 (18%) of 667 patients in 
high-income countries and 68 (3%) of 2395 patients in 
low-income and middle-income countries are using 
them, suggesting that factors in addition to availability 
and aﬀ ordability aﬀ ect the use of these medicines, and 
should be explored (appendix).
Discussion
The availability and aﬀ ordability of the four medicines 
recommended for the secondary prevention of 
cardiovascular disease greatly varies across the diﬀ erent 
country income groups. These medicines were more 
commonly available and aﬀ ordable in high-income 
countries, less so in upper middle-income countries and 
lower middle-income countries, and least available and 
aﬀ ordable in low-income countries (excluding India). 
Medicines were widely available in India, however, they 
were not aﬀ ordable, which was likely due to the low 
capacity-to-pay of households.
Of patients with known cardiovascular disease across 
18 countries studied in PURE, only 686 (10%) used three of 
the recommended medicines and 205 (3%) used all 
four medicines. In low-income and middle-income 
countries, there is a strong association between scarce 
availability and low aﬀ ordability of these medicines and 
their use. This ﬁ nding suggests that improvements in the 
availability and aﬀ ordability of these medicines are 
prerequisites to increasing their use. However, use of the 
recommended medicines was low in low-income and 
middle-income countries even when the medicines were 
potentially available and aﬀ ordable and only reached about 
18% use in high-income countries where these medicines 
are widely available and aﬀ ordable. Thus, although the 
availability and aﬀ ordability of medicines are prerequisites 
for their use, correcting these factors alone might not be 
suﬃ  cient to increase the proportion of patients receiving 
all medicines to optimum coverage. Other factors aﬀ ecting 
medicine use could include patients’ attitudes and 
knowledge towards taking medicines for prevention, and 
health-care providers’ attitudes and prescribing patterns.21 
Further studies are needed to understand how these 
factors aﬀ ect the use of medicines.
Our analyses are unique because we obtained 
standardised data for the availability, aﬀ ordability, and 
rates of use of the four medicines recommended for 
cardiovascular disease from 18 countries and 596 urban 
and rural communities. Standardised information 
about the availability and aﬀ ordability of cardiovascular 
disease medicines at the community level have 
previously been reported by the joint WHO and Health 
Number in group Participants using 
medicines*
Odds ratio (95% CI)
Unadjusted Adjusted†
Eﬀ ect on use of four medicines
Availability 6322 83 (1%) ·· ··
All four available (reference) 3637 74 (2%) 1·00 1·00
Fewer than four available 2685 9 (<1%) 0·16 (0·08–0·32) 0·16 (0·04–0·57)
Aﬀ ordability‡ 3637 83 (1%) ·· ··
Cost of four is aﬀ ordable (reference) 2395 68 (3%) 1·00 1·00
Cost of four is not aﬀ ordable 1242 6 (<1%) 0·17 (0·07–0·38) 0·16 (0·04–0·55)
Eﬀ ect on use of at least three medicines
Availability 6322 359 (6%) ·· ··
At least three available (reference) 4855 343 (7%) 1·00 1·00
Fewer than three available 1469 16 (1%) 0·14 (0·09–0·24) 0·11 (0·04–0·28)
Aﬀ ordability§ 4855 343 (7%) ·· ··
Cost of three is aﬀ ordable (reference) 4027 319 (8%) 1·00 1·00
Cost of three is not aﬀ ordable 828 24 (3%) 0·30 (0·19–0·46) 0·42 (0·22–0·80)
Four medicines are aspirin, β blockers, angiotensin-converting enzyme inhibitors, and statins. *Data are n (%) from 6322 patients. †Adjusted for age, sex, education years, 
years since diagnosis, cancer diagnosis, use of other medicines, smoking status, number of household members, urban versus rural location; clustered at the community and 
household levels. ‡Analyses restricted to 3637 patients living in communities where all four medicines were available. §Analyses restricted to 4855 patients living in 
communities in which at least three medicines were available.
Table 4: Associations between availability and aﬀ ordability and use of cardiovascular disease medicines in patients with a history of this disease in 
low-income and middle-income (including India) countries
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Action International project.20 However, unlike the 
PURE study, these data were not connected to rates of 
use among patients with cardiovascular disease. Our 
results support previous ﬁ ndings, suggesting that 
in low-income and middle-income countries the 
availability and aﬀ ordability of key medicines for the 
prevention of secondary cardiovascular disease events 
are low.20,22,23
Our results are based on observational analyses of 
cross-sectional data, and not from randomised controlled 
trials. Although our results show substantially lower use 
of key medicines when they are not available or 
unaﬀ ordable, it does not automatically mean that 
improvements in availability or aﬀ ordability by themselves 
will increase their use. Although improving availability 
and aﬀ ordability seems logical to improve the use of key 
medicines for secondary prevention of cardiovascular 
disease, additional factors (eg, access to health-care 
providers and attitudes to prevention on the part of both 
physicians and patients) are also likely to be important.
WHO’s Global Action Plan has set worldwide goals to 
achieve 80% availability of aﬀ ordable essential medicines 
for non-communicable diseases and 50% use of these 
medicines by 2025.5 Current rates of use of medicines for 
secondary prevention falls substantially short of these 
goals. Overcoming these large treatment gaps will 
initially need governments to set policies that make key 
medicines available and aﬀ ordable, followed by other 
strategies to enhance their use (eg, improving access to 
health-care providers, setting local targets for their use, 
and monitoring use).
Our results represent potential rather than true or 
actual availability and aﬀ ordability. If availability of 
medicines is higher in non-pharmacy vendors or in 
pharmacies not surveyed in our study, then our results 
might underestimate true availability. If patients 
received their medicines at a lower cost (or free of 
charge) in the public sector, our results might 
underestimate true aﬀ ordability. However, data from 
previous studies have shown that public sector 
availability of medicines tends to be low in low-income 
and middle-income countries,16 forcing patients to 
purchase their medicines from private pharmacies and 
at full cost. Data were collected from one pharmacy per 
community only, which might not be representative of 
true costs in the community. However, variations in 
costs between communities in the same country were 
small, suggesting that information from one pharmacy 
per community—in a large study like PURE—is a 
reasonable estimate of the estimated cost of medicines 
in a community.
By calculating aﬀ ordability based on only costs of 
medicines, we have likely overestimated aﬀ ordability 
because our approach does not take into account other 
medical costs, such as professional fees or travel or time 
taken oﬀ  work to visit a doctor. Our deﬁ nition of 
aﬀ ordability does not account for patient or household 
priorities. Even if these medicines are aﬀ ordable, patients 
might still judge them to be unaﬀ ordable if they have 
other household expenditures that they deem more 
important (eg, treatment of other diseases or costs of 
housing or education).
The PURE study did not gather data on other possible 
factors aﬀ ecting medicine use, such as patients’ attitudes 
and knowledge about their illness. These potential 
factors could explain some of the gaps in use even where 
medicines are available and aﬀ ordable. However, given 
the very large eﬀ ects of the availability and aﬀ ordability 
of medicines on use that we noted, availability and 
aﬀ ordability are likely to be essential factors inﬂ uencing 
medicine use.
The medicines assessed in this paper have been 
shown to prevent recurrent cardiovascular disease 
events and reduce mortality rates, and are recommended 
for use in most clinical guidelines. However, these 
medicines are not available in a large proportion of 
communities in low-income and middle-income 
countries and if available they are not always aﬀ ordable. 
Both low availability and aﬀ ordability are associated 
with low use of these medicines. Unless both availability 
and aﬀ ordability of these medicines are improved, their 
use is likely to remain low in most of the world.
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